GBS Inc. (GBS): Price and Financial Metrics
GET POWR RATINGS... FREE!
GBS Stock Price Chart Interactive Chart >
GBS Price/Volume Stats
| Current price | $3.12 | 52-week high | $14.24 |
| Prev. close | $3.26 | 52-week low | $2.44 |
| Day low | $3.10 | Volume | 400,300 |
| Day high | $3.28 | Avg. volume | 650,024 |
| 50-day MA | $3.27 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 38.63M |
GBS Inc. (GBS) Company Bio
GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It operates in Mainland China, Hong Kong, Vietnam, and Bangladesh. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Latest GBS News From Around the Web
Below are the latest news stories about GBS Inc that investors may wish to consider to help them evaluate GBS as an investment opportunity.
GBS Inc. to Present at Upcoming September Virtual Investor ConferencesH.C. Wainwright 23 rd Global Investor Conference: September 13 th - 15 th |
GBS Inc. to Present at Upcoming September Virtual Investor ConferencesH.C. Wainwright 23rd Global Investor Conference: September 13th - 15th Benzinga Healthcare Small Cap Conference: September 29th - 30th NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced its participation in the following investor conferences in the month of September and invites investors to join virtually. H.C. Wainwrigh |
21 Stocks Moving in Wednesday's Pre-Market SessionGainers GBS Inc. (NASDAQ: GBS) rose 72.3% to $5.58 in pre-market trading. The company markets saliva test for diabetes management and previously announced collaboration on covid-19 diagnostic with Harvard's Wyss Institute. Field Trip Health Ltd. (NASDAQ: FTRP) shares rose 30% to $6.25 in pre-market trading. HC Wainwright & Co. initiated coverage on Field Trip Health with a Buy rating and announced a price target of $20. Focus Universal Inc. (NASDAQ: FCUV) rose 25.1% to $6.38 in pre-market tradin |
Point of Care Testing Company GBS Develops Technology to Take the Fear out of Diabetes and COVID TestingGBS Inc. is presenting at the Benzinga Healthcare Small Cap Conference on September 29, 2021. For some people with diabetes, testing with a pinprick is no more than a minor inconvenience. But for many adults with testing phobias, they not only face the possibility of a rapid heartbeat or even passing out but could also skip much-needed glucose testing, putting their lives at risk. GBS Inc. (NASDAQ: GBS) understands that testing anxiety can be a life-or-death dilemma and is on a mission to develo |
GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights- Awarded $4.7 Million Government Grant Funding to support the building of a high-tech manufacturing facility - |
GBS Price Returns
| 1-mo | 7.59% |
| 3-mo | -16.80% |
| 6-mo | -51.78% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -57.84% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...